In the last trading session, 0.15 million shares of the Prelude Therapeutics Inc (NASDAQ:PRLD) were traded, and its beta was 1.38. Most recently the company’s share price was $1.05, and it changed around $0.03 or 2.94% from the last close, which brings the market valuation of the company to $57.79M. PRLD currently trades at a discount to its 52-week high of $6.80, offering almost -547.62% off that amount. The share price’s 52-week low was $0.80, which indicates that the current value has risen by an impressive 23.81% since then. We note from Prelude Therapeutics Inc’s average daily trading volume that its 10-day average is 0.26 million shares, with the 3-month average coming to 483.39K.
Prelude Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 3.00. If we narrow it down even further, the data shows that 1 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended PRLD as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight.
Prelude Therapeutics Inc (NASDAQ:PRLD) trade information
Instantly PRLD has showed a green trend with a performance of 2.94% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.0800 on recent trading dayincreased the stock’s daily price by 2.78%. The company’s shares are currently down -17.65% year-to-date, but still down -0.94% over the last five days. On the other hand, Prelude Therapeutics Inc (NASDAQ:PRLD) is 17.23% up in the 30-day period. We can see from the shorts that 3.38 million shares have been sold at a short interest cover period of 4.46 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 79.0% from its current value. Analyst projections state that PRLD is forecast to be at a low of $5 and a high of $5.
Prelude Therapeutics Inc (PRLD) estimates and forecasts
Prelude Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -80.04 percent over the past six months and at a 10.40% annual growth rate that is well below the industry average of 16.60%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.14%.
PRLD Dividends
Prelude Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Prelude Therapeutics Inc (NASDAQ:PRLD)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.36% of Prelude Therapeutics Inc shares, and 84.98% of them are in the hands of institutional investors. The stock currently has a share float of 93.76%. Prelude Therapeutics Inc stock is held by 102.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 14.4043% of the shares, which is about 10.91 million shares worth $41.56 million.
BAKER BROS. ADVISORS LP, with 13.3673% or 10.12 million shares worth $38.57 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
